LifeStance Health Group (NASDAQ:LFST – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $13.00 to $15.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a neutral rating on the stock.
Several other equities analysts have also recently weighed in on the company. Barclays lifted their target price on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. BTIG Research upped their target price on LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Canaccord Genuity Group increased their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Weiss Ratings restated a “hold (c)” rating on shares of LifeStance Health Group in a report on Wednesday, November 4th. Finally, KeyCorp raised their price target on shares of LifeStance Health Group from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $14.86.
Check Out Our Latest Stock Analysis on LFST
LifeStance Health Group Stock Performance
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The firm had revenue of $455.86 million for the quarter, compared to analyst estimates of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The firm’s revenue was up 25.3% compared to the same quarter last year. On average, sell-side analysts anticipate that LifeStance Health Group will post 0.18 EPS for the current fiscal year.
Insider Buying and Selling at LifeStance Health Group
In other LifeStance Health Group news, COO Lisa K. Miller sold 14,663 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $14.68, for a total value of $215,252.84. Following the transaction, the chief operating officer owned 251,904 shares in the company, valued at $3,697,950.72. The trade was a 5.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Vukasin Paunovich sold 42,067 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the transaction, the chief technology officer owned 205,379 shares in the company, valued at $2,643,227.73. This trade represents a 17.00% decrease in their position. The SEC filing for this sale provides additional information. 3.50% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On LifeStance Health Group
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of LifeStance Health Group in the 2nd quarter valued at approximately $389,293,000. Dimensional Fund Advisors LP raised its position in LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after acquiring an additional 1,461,215 shares in the last quarter. Jennison Associates LLC raised its position in LifeStance Health Group by 38.5% during the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after acquiring an additional 2,843,388 shares in the last quarter. Voya Investment Management LLC lifted its stake in LifeStance Health Group by 1,249.6% in the third quarter. Voya Investment Management LLC now owns 3,971,989 shares of the company’s stock valued at $47,783,000 after acquiring an additional 3,677,679 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in LifeStance Health Group in the second quarter valued at approximately $30,881,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.
About LifeStance Health Group
LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.
Recommended Stories
- Five stocks we like better than LifeStance Health Group
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
